{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 346, "pageCount": 415, "prevPage": 345, "nextPage": 347, "slideType": "testimonial", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses highlighted text to emphasize critical quotes from medical experts.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/346", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-346", "components": [ { "bbox": null, "kind": "callout", "text": "these specialists are going to be asked for their opinion in public fora...And a couple of these comments are going to torpedo the launch program for Soleno.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b3-a6c2b06bfe1b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.35 }, "kind": "paragraph", "text": "Ambivalent about the trial data to begin with; concerned about now understanding it properly vs. “marketing messages”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8c84a99f-70ea-4c84-a110-24cbb429af62", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.68 }, "kind": "quote", "text": "Endocrinologist highly concerned after trial investigators’ feedback regarding their intent to use the drug “It’s very compelling that a high-volume specialist who has experience with the drug in the clinical trials indicates that their observed efficacy endpoints were modest to mild, to maybe even near zero, and that they aren’t excited about this medication for their patients, and certainly not at this price point. What I imagine is going to happen is exactly that these specialists are going to be asked for their opinion in public fora, or ask questions in public fora to say, well, what do you think? What was your experience with these patients and this drug? And a couple of these comments are going to torpedo the launch program for Soleno.” – Endocrinologist with academic and community hospital affiliations", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "813ed301-b092-4ead-a80c-ec6ce72f2f48", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.4 }, "kind": "quote", "text": "Q: “When you said it works for hyperphagia, were you aware that the trial failed in hyperphagia and it only worked in a subgroup? Or were you not aware of that? You might not have read the pivotal paper.” A: “Well, a couple of things. I remember that diazoxide trials a few years ago failed...these are not well-recognized journals or high-quality data points. I find it very interesting that there may be some internal inconsistencies that I am unaware of, and I’m now quite curious about finding out more of this background to help me understand the right thing to do for my patients based on primary endpoint analysis, not just on marketing messages.” – Endocrinologist with academic and community hospital affiliations", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f6f293fd-5f81-4de5-b2a7-1b2ca1062308", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“Well, a couple of things. I remember that diazoxide trials a few years ago failed...these are not well-recognized journals or high-quality data points. I find it very interesting that there may be some internal inconsistencies that I am unaware of, and I’m now quite curious about finding out more of this background to help me understand the right thing to do for my patients based on primary endpoint analysis, not just on marketing messages.” — Endocrinologist with academic and community hospital affiliations", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b3-abca73b3ef16", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "1d78198c-2f5e-41d8-9ce8-6a018c339c3f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "Endocrinologist #1: Skeptical of Soleno’s marketing messages and concerned that other trial investigators are similarly skeptical; thinks that comments by these investigators “in a public fora” are “going to torpedo the launch program for Soleno”", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "49940870-0c66-4274-bc8b-2bcf29db916b", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }